港股异动 | 歌礼制药-B(01672)盘中再涨近13% Sagimet公布治疗NASH试验积极结果
歌礼制药-B(01672)盘中再涨近13%，截至发稿，涨7.36%，报1.75港元，成交额578.72万港元。
消息面上，本周一，Sagimet Biosciences(SGMT.US)暴涨170%，收报18.42美元。公司报告了其主要候选药物Denifanstat在某些非酒精性脂肪性肝炎(NASH)慢性肝病患者中进行的2b期的积极结果。Denifanstat在2期或3期纤维化的经活检证实的NASH患者中，相对于安慰剂在的两个主要终点上显示出了统计学上的显著改善。
招股书显示，Sagimet与合作伙伴中国公司歌礼制药就Denifanstat在NASH，痤疮，复发脑胶质瘤等多个领域开展了临床。此外，1月2日，歌礼宣布了NASH药物ASC41片用于治疗经肝穿活检证实的NASH患者的52周Ⅱ期临床试验取得积极期中结果。歌礼制药介绍，该药属于甲状腺激素受体β激动剂，具有肝脏靶向性和高度的THRβ选择性。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.